The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) hit a new 52-week low and has $2.63 target or 11.00% below today’s $2.95 share price. The 8 months bearish chart indicates high risk for the $299.46M company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $2.63 price target is reached, the company will be worth $32.94 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 2.09 million shares traded hands. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.25% since April 1, 2016 and is downtrending. It has underperformed by 21.47% the S&P500.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage
Out of 11 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 6 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 55% are positive. $42 is the highest target while $4 is the lowest. The $22.56 average target is 664.75% above today’s ($2.95) stock price. Celldex Therapeutics has been the topic of 15 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The company was maintained on Tuesday, August 11 by Brean Capital. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Hold” rating by Jefferies on Tuesday, August 9. Cowen & Co maintained the shares of CLDX in a report on Tuesday, March 8 with “Outperform” rating. The firm earned “Hold” rating on Tuesday, March 8 by Jefferies. Leerink Swann downgraded Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Monday, March 7 to “Market Perform” rating. Guggenheim downgraded the stock to “Neutral” rating in Monday, March 7 report. The rating was maintained by H.C. Wainwright on Tuesday, March 8 with “Buy”. Cantor Fitzgerald maintained the shares of CLDX in a report on Friday, February 26 with “Buy” rating. The rating was maintained by TH Capital on Tuesday, August 11 with “Buy”. Wedbush downgraded the stock to “Neutral” rating in Monday, March 7 report.
According to Zacks Investment Research, “CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.”
More news for Celldex Therapeutics, Inc. (NASDAQ:CLDX) were recently published by: Fool.com, which released: “Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc.” on October 25, 2016. Fool.com‘s article titled: “Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc.” and published on October 18, 2016 is yet another important article.
CLDX Company Profile
Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Firm drug candidates are derived from a set of complementary technologies, which have the ability to utilize the human immune system and enable the creation of therapeutic agents. The Firm is using the technologies to develop targeted immunotherapeutics consist of protein molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). The Company’s Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. The Company’s Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.